Introduction
============

Mucoepidermoid carcinoma (MEC) is the most common salivary gland malignancy. About 50% MEC occurs in the major salivary glands, with 70% in the parotid gland ([@ref-16]; [@ref-5]). Surgery is still the mainstay of treatment for malignant salivary gland tumors. The selection of surgical procedure depends on the location and grade of the tumor. Most parotid tumors are confined to the superficial lobe and require a superficial parotidectomy, while only 10% to 20% of tumors involve the deep lobe, which requires a total gland resection ([@ref-11]; [@ref-15]). Postoperative radiotherapy has shown a survival benefit in patients with major salivary gland carcinoma. Indications of postoperative radiotherapy include positive or close margin (\<0.5 cm), high grade, skin or bone infiltration, perineural invasion and lymph node metastases. Chemotherapy is mainly used in the palliative setting. However, even after surgical resection and postoperative radiotherapy, 40% of cases relapse ([@ref-9]).

The prognostic factors of parotid gland mucoepidermoid carcinoma (P-MEC) included sex, age, histological grade and surgical margins ([@ref-16]; [@ref-7]). Usually, low grade P-MEC patients exhibit a better survival than high grade P-MEC patients. However, survival is also good even in high grade P-MEC patients diagnosed with an early stage malignancy ([@ref-13]). [@ref-6] reported a better overall survival in P-MEC patients who were 54 years old or younger, female, non-white , with no comorbidities according to the Charlson/Deyo score, suffering from low grade P-MEC, with an early stage tumor and who had a negative surgical margin. To date, large-scale studies on the prognostic factors for P-MEC are limited and the reported associations have not been confirmed ([@ref-6]).

Nomography has been widely used to predict the survival of cancer patients ([@ref-8]; [@ref-19]; [@ref-20]). However, a nomogram for P-MEC has not been developed. Therefore, we constructed a nomogram to visually predict the 5- and 10-year overall survival rate of P-MEC patients using data from the Surveillance, Epidemiology, and End Results (SEER) database. We expect that our research will improve the understanding of P-MEC and optimize individual therapies and follow-up.

Patients and Methods
====================

Ethics statement
----------------

Approval for use of all data was obtained by submitting a request to the SEER program. No approval by the institutional review board was sought since SEER is a public database.

Patients
--------

Data were extracted using SEER\*Stat software (version 8.3.5) from the SEER Program (<http://www.seer.cancer.gov>) SEER\*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2017 Sub (1973--2015, varying) - Linked To County Attributes - Total U.S., 1969--2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission.

Cases in which the primary site of the parotid gland were selected using the variable "primary site" (parotid gland = 079). Cases in which P-MEC were identified by histology (International Classification of Diseases code: 8430) ([@ref-5]). Cases were excluded if: the AJCC 7th TNM stage data were not complete; they had more than one malignancy, a survival time of three months or less, were not diagnosed with microscopic confirmation by histology or cytology and the grade, T stage, N stage, M stage, race, and laterality were unknown ([@ref-10]; [@ref-12]). Detailed information regarding age, sex, laterality, race, marital status, grade, radiotherapy, chemotherapy, surgery, and the AJCC 7th TNM stage were extracted ([Fig. 1](#fig-1){ref-type="fig"}).

Statistical analysis
--------------------

The survival time was calculated from diagnosis to death or to the end of the study period. Overall survival (OS) and cancer-specific survival (CSS) rates were estimated using the Kaplan--Meier method. Survival curves were compared using the log-rank test for significance. Univariate and multivariate hazard analysis was conducted using the cox proportional hazards model to identify independent prognostic factors. The power analysis was completed with PASS (version 11). All other statistical analyses were performed using SPSS (version 24; IBM, Armonk, NY, USA). A probability value (*p* value) of \<0.05 was considered statistically significant for all tests. All tests were two-sided.

Nomogram Construction and Validation
------------------------------------

We built a nomogram based the results of multivariate hazard analysis via the rms package of R, version 3.4.4 ([@ref-17]). The maximum score for each variable was set at 10. Accuracy of the nomogram was assessed based on the Harrel concordance index (C-index) and calibration curves were calculated by regression analysis to compare the nomogram-predicted and Kaplan--Meier estimated survival probability. Bootstraps of 1,000 re-samples were set.

![The flow diagram of the selection process for the study cohort.](peerj-07-7237-g001){#fig-1}

Results
=======

Patient clinicopathological data
--------------------------------

A total of 1,306 cases of P-MEC diagnosed between 2004 and 2015 were enrolled. Demographic information is provided in [Table 1](#table-1){ref-type="table"}. The median age was 53 years with a standard deviation of 19.6 years. Among the 1,306 cases, 660 (50.5%) patients were female, 680 (52.1%) patients had tumors originating from the right parotid gland, and 1,286 (98.5%) patients received surgery. Additionally, 609 (46.6%) and 81 (6.2%) patients received radiotherapy and chemotherapy, respectively. As for the AJCC 7th staging information, there were 573 (43.8%) cases with stage I, 296 (22.7%) cases with stage II, 200 (15.3%) cases with stage III,194 (14.9%) cases with stage IVA, 25 (1.9%) cases with stage IVB, and 18 (1.4%) cases with stage IVC P-MEC. Concerning grade, 362 (27.7%) cases were well differentiated (grade I), 608 (46.5%) cases were moderately differentiated (grade II), 168 (12.9%) cases were poorly differentiated (grade III), and 168 (12.9) cases were undifferentiated (grade IV).

Survival analysis
-----------------

The median follow-up period was 54 months (4--143 months). The 5-year OS and CSS were 83.1% and 88.7%, respectively. The 10-year OS and CSS were 73.6% and 86.4%, respectively.

Univariate analysis showed that age (*p* \< 0.001), sex (*p* \< 0.001), race (*p* = 0.006), grade (*p* \< 0.001), TNM stage (*p* \< 0.001), T stage (*p* \< 0.001), N stage (*p* \< 0.001), M stage (*p* \< 0.001), radiotherapy (*p* \< 0.001), chemotherapy (*p* \< 0.001), and surgery (*p* \< 0.001) were significant prognostic factors of OS ([Table 2](#table-2){ref-type="table"}). Furthermore, age (*p* \< 0.001), sex (*p* \< 0.001), race (*p* = 0.010), grade (*p* \< 0.001), TNM stage (*p* \< 0.001), T stage (*p* \< 0.001), N stage (*p* \< 0.001), M stage (*p* \< 0.001), radiotherapy (*p* \< 0.001), chemotherapy (*p* \< 0.001), and surgery (*p* \< 0.001) were significant prognostic factors for CSS ([Table 3](#table-3){ref-type="table"}). Related clinic pathological factors with p-values (*p* \< 0.05) in the univariate analyses were adjusted for multivariate analysis. After multivariate analysis, only age (*p* \< 0.001), grade (*p* \< 0.001), T stage (*p* \< 0.001), N stage (*p* \< 0.001), M stage (*p* = 0.002), chemotherapy (*p* = 0.005), and surgery (*p* = 0.011) remained independent prognostic factors for OS ([Table 2](#table-2){ref-type="table"}). Similarly, age (*p* \< 0.001), grade (*p* \< 0.001), T stage (*p* = 0.002), N stage (*p* \< 0.001), M stage (*p* = 0.002), chemotherapy (*p* = 0.006) and surgery (*p* = 0.043) remained independent prognostic factors for CSS ([Table 3](#table-3){ref-type="table"}). As shown in [Fig. 2](#fig-2){ref-type="fig"}, patients who were younger, with a lower grade, early stage, no chemotherapy, and surgery had a significantly better OS.
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###### Characteristics of patients with parotid mucoepidermoid carcinoma.

![](peerj-07-7237-g005)

  Characteristics    Number   Percent (%)
  ------------------ -------- -------------
  Age                         
  \<40 years         355      27.182
  40--49 years       207      15.850
  50--59 years       256      19.602
  60--69 years       215      16.462
  ≥70 years          273      20.904
  Sex                         
  Male               646      49.464
  Female             660      50.536
  Laterality                  
  Left               626      47.933
  Right              680      52.067
  Race                        
  White              985      75.421
  Black              174      13.323
  Other              147      11.256
  Marital status              
  Married            705      53.982
  Not married        553      42.343
  Unknown            48       3.675
  Grade                       
  I                  362      27.718
  II                 608      46.554
  III                168      12.864
  IV                 168      12.864
  TNM stage                   
  I                  573      43.874
  II                 296      22.664
  III                200      15.314
  IVA                194      14.854
  IVB                25       1.914
  IVC                18       1.380
  T stage                     
  T1                 605      46.325
  T2                 363      27.795
  T3                 188      14.395
  T4a                129      9.877
  T4b                21       1.608
  N stage                     
  N0                 1058     81.011
  N1                 124      9.494
  N2a                6        0.459
  N2b                110      8.423
  N2c                3        0.230
  N3                 5        0.383
  M stage                     
  M0                 1288     98.622
  M1                 18       1.378
  Radiotherapy                
  No                 697      53.369
  Yes                609      46.631
  Chemotherapy                
  No                 1225     93.798
  Yes                81       6.202
  Surgery                     
  No                 20       1.531
  Yes                1286     98.469
  Cause of death              
  Alive              1081     82.772
  Cancer death       137      10.490
  Non-cancer death   88       6.738
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###### Parotid mucoepidermoid carcinoma: univariate and multivariate analysis of overall survival.
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                   Univariate   *P*              Power value                                 Multivariate   *P*         Power value                                                 
  ---------------- ------------ ---------------- ------------------------------------------- -------------- ----------- --------------- ------------------------------------------- -------
  Age                                            \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                              \<0.001[^\*^](#table-2fn2){ref-type="fn"}   
  \<40 years       Reference                                                                                Reference                                                               
  40--49 years     1.433        0.663--3.098     0.361                                       1.000          1.055       0.478--2.329    0.895                                       1.000
  50--59 years     2.773        1.454--5.288     0.002                                       1.000          2.068       1.064--4.019    0.032[^\*^](#table-2fn2){ref-type="fn"}     1.000
  60--69 years     6.068        3.319--11.094    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          3.591       1.904--6.771    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000
  ≥70 years        16.582       9.542--28.818    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          9.262       5.125--16.739   \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000
  Sex                                            \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                              0.384                                       
  Male             Reference                                                                                Reference                                                               
  Female           0.493        0.375--0.649     \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          1.139       0.850--1.525    0.384                                       1.000
  Laterality                                     0.333                                                                                                                              
  Left             Reference                                                                                                                                                        
  Right            0.879        0.677--1.142     0.333                                       1.000                                                                                  
  Race                                           0.006[^\*^](#table-2fn2){ref-type="fn"}                                                0.587                                       
  White            Reference                                                                                Reference                                                               
  Black            0.575        0.359--0.921     0.021[^\*^](#table-2fn2){ref-type="fn"}     1.000          0.785       0.457--1.347    0.379                                       1.000
  Other            0.577        0.347--0.962     0.035[^\*^](#table-2fn2){ref-type="fn"}     1.000          1.126       0.667--1.899    0.657                                       1.000
  Marital status                                 0.252                                                                                                                              
  Married          Reference                                                                                                                                                        
  Not married      1.176        0.899--1.537     0.237                                       1.000                                                                                  
  Unknown          1.578        0.827--3.013     0.166                                       1.000                                                                                  
  Grade                                          \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                              \<0.001[^\*^](#table-2fn2){ref-type="fn"}   
  I                Reference                                                                                Reference                                                               
  II               2.233        1.216--4.102     0.010[^\*^](#table-2fn2){ref-type="fn"}     1.000          1.824       0.981--3.392    0.058                                       1.000
  III              15.638       8.691--28.138    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          4.112       2.107--8.026    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000
  IV               18.027       10.038--32.375   \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          5.236       2.687--10.204   \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000
  TNM stage                                      \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                                                                          
  I                Reference                                                                                                                                                        
  II               2.032        1.250--3.305     0.004[^\*^](#table-2fn2){ref-type="fn"}     1.000                                                                                  
  III              5.386        3.493--8.305     \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000                                                                                  
  IVA              8.902        5.892--13.450    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000                                                                                  
  IVB              9.067        4.456--18.452    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000                                                                                  
  IVC              54.136       29.337--99.900   \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000                                                                                  
  T stage                                        \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                              \<0.001[^\*^](#table-2fn2){ref-type="fn"}   
  T1               Reference                                                                                Reference                                                               
  T2               2.509        1.670--3.771     \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          1.605       1.043--2.470    0.031[^\*^](#table-2fn2){ref-type="fn"}     1.000
  T3               6.401        4.307--9.513     \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          2.690       1.729--4.184    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000
  T4a              7.813        5.174--11.797    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          1.844       1.145--2.970    0.012[^\*^](#table-2fn2){ref-type="fn"}     1.000
  T4b              8.761        4.241--18.097    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          2.645       1.178--5.939    0.018[^\*^](#table-2fn2){ref-type="fn"}     1.000
  N stage                                        \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                              \<0.001[^\*^](#table-2fn2){ref-type="fn"}   
  N0               Reference                                                                                Reference                                                               
  N1               4.423        3.170--6.171     \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          1.849       1.277--2.677    0.001[^\*^](#table-2fn2){ref-type="fn"}     1.000
  N2a              7.823        2.884--21.223    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          1.164       0.403--3.356    0.779                                       0.791
  N2b              6.893        4.985--9.532     \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          2.321       1.598--3.370    \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000
  N2c              7.430        1.035--53.312    0.046[^\*^](#table-2fn2){ref-type="fn"}     1.000          2.838       0.381--21.121   0.308                                       1.000
  N3               4.346        1.073--17.597    0.039[^\*^](#table-2fn2){ref-type="fn"}     1.000          1.211       0.282-5.204     0.797                                       0.993
  M stage                                        \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                              0.002[^\*^](#table-2fn2){ref-type="fn"}     
  M0               Reference                                                                                Reference                                                               
  M1               17.167       10.189--28.924   \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          3.104       1.526--6.314    0.002[^\*^](#table-2fn2){ref-type="fn"}     1.000
  Radiotherapy                                   \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                              0.722                                       
  No               Reference                                                                                Reference                                                               
  Yes              2.541        1.922--3.360     \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          0.940       0.666--1.325    0.722                                       0.958
  Chemotherapy                                   \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                              0.005[^\*^](#table-2fn2){ref-type="fn"}     
  No               Reference                                                                                Reference                                                               
  Yes              5.279        3.789--7.354     \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          1.739       1.178--2.567    0.005[^\*^](#table-2fn2){ref-type="fn"}     1.000
  Surgery                                        \<0.001[^\*^](#table-2fn2){ref-type="fn"}                                              0.011[^\*^](#table-2fn2){ref-type="fn"}     
  No               Reference                                                                                Reference                                                               
  Yes              0.102        0.060--0.172     \<0.001[^\*^](#table-2fn2){ref-type="fn"}   1.000          0.404       0.202--0.810    0.011[^\*^](#table-2fn2){ref-type="fn"}     1.000

**Notes.**

HRhazard ratioCIconfidence interval

indicates *p* \< 0.05.
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###### Parotid mucoepidermoid carcinoma: univariate and multivariate analysis of cancer specific survival.
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                   Univariate   *P*                    Power value                                 Multivariate   *P*         Power value                                                        
  ---------------- ------------ ---------------------- ------------------------------------------- -------------- ----------- ---------------------- ------------------------------------------- -------
  Age                                                  \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                     \<0.001[^\*^](#table-3fn2){ref-type="fn"}   
  \<40 years       Reference                                                                                      Reference                                                                      
  40--49 years     1.675        0.665--4.219           0.274                                       1.000          0.900       0.337--2.402           0.833                                       1.000
  50--59 years     3.151        1.435--6.921           0.004                                       1.000          1.698       0.740--3.895           0.212                                       1.000
  60--69 years     6.530        3.108--13.719          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          2.555       1.148--5.691           0.022[^\*^](#table-3fn2){ref-type="fn"}     1.000
  ≥70 years        12.536       6.249--25.147          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          4.376       2.041--9.384           \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000
  Sex                                                  \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                     0.086                                       
  Male             Reference                                                                                      Reference                                                                      
  Female           0.507        0.357--0.721           \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          1.386       0.954--2.012           0.086                                       1.000
  Laterality                                           0.647                                                                                                                                     
  Left             Reference                                                                                                                                                                     
  Right            1.081        0.773--1.513           0.647                                       0.983                                                                                         
  Race                                                 0.010[^\*^](#table-3fn2){ref-type="fn"}                                                       0.277                                       
  White            Reference                                                                                      Reference                                                                      
  Black            0.530        0.286--0.983           0.044[^\*^](#table-3fn2){ref-type="fn"}     1.000          0.538       0.251--1.151           0.110                                       1.000
  Other            0.466        0.228--0.953           0.037[^\*^](#table-3fn2){ref-type="fn"}     1.000          0.979       0.469--2.046           0.955                                       0.170
  Marital status                                       0.406                                                                                                                                     
  Married          Reference                                                                                                                                                                     
  Not married      0.949        0.670--1.346           0.770                                       0.722                                                                                         
  Unknown          1.627        0.750--3.531           0.218                                       1.000                                                                                         
  Grade                                                \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                     \<0.001[^\*^](#table-3fn2){ref-type="fn"}   
  I                Reference                                                                                      Reference                                                                      
  II               16512.147    0.000--2.850 ×10^34^   0.785                                       1.000          11177.452   0.000--3.439 ×10^32^   0.781                                       1.000
  III              166824.855   0.000--2.878 ×10^35^   0.735                                       1.000          32679.182   0.000--1.006 ×10^33^   0.756                                       1.000
  IV               216497.486   0.000--3.734 ×10^35^   0.729                                       1.000          46748.769   0.000--1.439 ×10^35^   0.748                                       1.000
  TNM stage                                            \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                                                                 
  I                Reference                                                                                                                                                                     
  II               1.964        0.817--4.719           0.131                                       1.000                                                                                         
  III              11.051       5.495--22.222          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000                                                                                         
  IVA              20.528       10.480--40.212         \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000                                                                                         
  IVB              25.339       10.292--62.385         \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000                                                                                         
  IVC              127.682      56.104--290.581        \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000                                                                                         
  T stage                                              \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                     0.002[^\*^](#table-3fn2){ref-type="fn"}     
  T1               Reference                                                                                      Reference                                                                      
  T2               2.889        1.557--5.363           \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          1.314       0.685--2.518           0.411                                       1.000
  T3               10.764       6.102--18.988          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          2.866       1.550--5.300           0.001[^\*^](#table-3fn2){ref-type="fn"}     1.000
  T4a              13.467       7.524--24.105          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          2.015       1.046--3.881           0.036[^\*^](#table-3fn2){ref-type="fn"}     1.000
  T4b              18.201       7.786--42.548          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          2.688       1.011--7.144           0.047[^\*^](#table-3fn2){ref-type="fn"}     1.000
  N stage                                              \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                     \<0.001[^\*^](#table-3fn2){ref-type="fn"}   
  N0               Reference                                                                                      Reference                                                                      
  N1               8.221        5.376--12.572          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          2.513       1.571--4.018           \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000
  N2a              14.477       4.501--46.559          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          1.996       0.571--6.983           0.279                                       1.000
  N2b              12.716       8.435--19.171          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          3.192       2.004--5.084           \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000
  N2c              15.657       2.156--113.727         0.007[^\*^](#table-3fn2){ref-type="fn"}     1.000          3.691       0.481--28.309          0.209                                       1.000
  N3               10.499       2.549--43.250          0.001[^\*^](#table-3fn2){ref-type="fn"}     1.000          2.338       0.521--10.497          0.268                                       1.000
  M stage                                              \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                     0.002[^\*^](#table-3fn2){ref-type="fn"}     
  M0               Reference                                                                                      Reference                                                                      
  M1               21.597       12.256--38.057         \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          3.554       1.602--7.885           0.002[^\*^](#table-3fn2){ref-type="fn"}     1.000
  Radiotherapy                                         \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                     0.763                                       
  No               Reference                                                                                      Reference                                                                      
  Yes              3.965        2.669--5.891           \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          1.078       0.661--1.757           0.763                                       0.998
  Chemotherapy                                         \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                     0.006[^\*^](#table-3fn2){ref-type="fn"}     
  No               Reference                                                                                      Reference                                                                      
  Yes              7.766        5.332--11.311          \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          1.865       1.196--2.906           0.006[^\*^](#table-3fn2){ref-type="fn"}     1.000
  Surgery                                              \<0.001[^\*^](#table-3fn2){ref-type="fn"}                                                     0.043[^\*^](#table-3fn2){ref-type="fn"}     
  No               Reference                                                                                      Reference                                                                      
  Yes              0.080        0.044--0.145           \<0.001[^\*^](#table-3fn2){ref-type="fn"}   1.000          0.423       0.184--0.975           0.043[^\*^](#table-3fn2){ref-type="fn"}     1.000

**Notes.**

HRhazard ratioCIconfidence interval

indicates *p* \< 0.05.

![Overall Kaplan--Meier survival curves according to age (A), grade (B), T stage (C), N stage (D), M stage (E), surgery type (F) and chemotherapy (G).](peerj-07-7237-g002){#fig-2}

The 5- and 10-year OS consisted of T1 stage (93.3% and 87.3%), T2 stage (86.2% and 75.1%), T3 stage (65.8% and 53.0%), T4 stage (58.7% and 45.4%), N0 stage (90.0% and 81.3%), N1 stage (59.6% and 48.0%), N2 stage (49.2% and 34.6%), and M0 stage (84.3% and 74.6%). Because of the limited number of M1 stage cases, we only observed the 5-year OS (12%). The 5- and 10-year OS also differed greatly between grade I (97.4% and 89.8%), grade II (92.9% and 85.2%), grade III (55.1% and 38.2%), and grade IV (48.8% and 39%).

Establishment and validation of the nomogram
--------------------------------------------

According to the multivariate analysis, a nomogram for OS was established ([Fig. 3](#fig-3){ref-type="fig"}). To estimate the 5- and 10-year OS rates, we identified the score for each factor based on the points scale at the top of the nomogram and the sum of the points for each factor. Then, we estimated the 5- and 10-year OS rates based on the points scale at the bottom of the nomogram. The calibration plot based on bootstrap re-sampling validation demonstrated a good agreement between the nomogram-predicted and observed survival rates ([Fig. 4](#fig-4){ref-type="fig"}). The C-index was 0.8777 (95% CI \[0.855--0.898\]), suggesting that the nomogram was an accurate model for predicting OS.

![Nomogram of prediction for 5-year and 10-year overall survival.](peerj-07-7237-g003){#fig-3}

![Calibration curves of the nomogram-predicted 5-year (A) and 10-year (B) overall survival.](peerj-07-7237-g004){#fig-4}

Discussion
==========

MEC accounts for 30%--40% of all malignant tumors of salivary glands. About 70% of MEC in major salivary glands occurs in the parotid gland ([@ref-2]; [@ref-14]). In this study, using more than 1,000 cases from the SEER database, we identified age, grade, T stage, N stage, M stage, chemotherapy, and surgery as independent prognostic factors for both OS and CSS, based on which a nomogram was established to visually and effectively predict the 5- and 10-year OS of patients with P-MEC. To our knowledge, this is the first large-scale population-based study to investigate the prognostic factors and construct a prognostic nomogram that visually and effectively predicts the 5- and 10-year OS of patients with P-MEC. With such a nomogram, we may accurately predict the OS of a P-MEC patient easily with his personalized clinical parameters.

Similar to our results, [@ref-1] reported that the 5-year OS of P-MEC was 81.5%. However, the 10-year OS of P-MEC in their research was 63.5%., which was 73.6% in our study. In our opinion, it may be the reason that they analyzed the survival of patients diagnosed between 1988 and 1998, which was analyzed for patients diagnosed between 2004 and 2015. Undoubtedly, the survival of P-MEC patients were prominently improved with the rapid development of medical science.

Surgical resection remains a cornerstone in the care of patients with P-MEC. In agreement with our results, Rajasekaran et al. reported that the 5-year overall survival was significantly better for patients with surgically resected P-MEC than those with surgery combined with radiotherapy or chemotherapy and without treatment ([@ref-16]). Additionally, they found that patients with increasing age, higher grade, and advanced T, N stage exhibited a worse survival. [@ref-1] also demonstrated that age grade and extraglandular extension. Traditionally, radiotherapy was applied in P-MEC patients with high grade, advanced stage, and unresectable and recurrent tumors. Nevertheless, radiotherapy may result in fatigue and pain, ototoxicity, xerostomia, radiation fibrosis, and radiation-induced malignancy ([@ref-4]; [@ref-3]; [@ref-21]). [@ref-21] reported that P-MEC patients with negative but close (≤2 mm) surgical margins without other high-risk histopathological factors did not benefit from adjuvant radiation in terms of long-term locoregional control. [@ref-18] exhibited a significantly improved 10-year local control in T3-4 tumors, close and incomplete resected tumors, and tumors with bone invasion or perineural invasion for patients with malignant salivary gland tumors who received postoperative radiation than those treated with surgery alone. They recommended a dose of at least 60 Gy adjuvant radiation for these patients ([@ref-18]). In agreement with our research, [@ref-1] also failed to observe the independently prognostic role of radiotherapy for OS in patients with P-MEC. There was little efficacy data for chemotherapy in patients with P-MEC published. It was usually applied as a palliative treatment in patients at advanced stage. We observed that P-MEC patients with chemotherapy exhibited a significantly worse survival. There was still no large series about the efficacy of radiotherapy and chemotherapy for P-MEC, which thus required further researches.

Consistent with our findings, several studies had identified the grade as an important prognostic factor for patients with P-MEC ([@ref-16]; [@ref-5]; [@ref-1]). [@ref-5] found that high grade P-MEC was significantly associated with a decreased CSS. [@ref-1] revealed that high grade P-MEC had a significantly worse OS. We also observed that patients with grade III/IV P-MEC had a significantly worse OS than patients with grade I/II tumors.

There were several limitations to this study. First, our study was retrospective with some inevitable bias. Indeed, a larger randomized study is needed to validate our results. Second, the variables which had a great impact on survival to identify the sequence of surgery and chemotherapy and the chemotherapeutic agents with a great impact on survival are not available from the SEER database. Third, other factors may influence the prognosis, such as the surgical margin status, nutritional status, socioeconomic status, drinking and smoking and so on, are not available from the SEER database. Besides, the enrolled patients in our research were all from America, which were mainly the white race. Thus, the reference function of our nomogram may be limited and further comprehensive research is needed to identify these prognostic factors and improve the nomogram.

Conclusions
===========

We showed that age, grade, T stage, N stage, M stage, chemotherapy and surgery are independent prognostic factors for OS and CSS rates in more than 1,000 American patients with P-MEC. Furthermore, we developed a nomogram that effectively and visually predicts the 5- and 10-year OS in such patients with P-MEC, which could also provide a prognostic reference for other P-MEC patients.
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